• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>British Journal of Cancer >Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy.
【2h】

Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy.

机译：前列腺癌的DNA倍性和S期分数的流式细胞仪分析：对内分泌治疗的预后和反应的意义。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We analysed ploidy and S-phase fraction (SPF) from 78 paraffin-embedded primary prostatic carcinomas by DNA flow cytometry. DNA aneuploidy and above median (4.2%) SPF were both associated with high tumour grade, large size of prostate and presence of distant metastases. Both aneuploidy and high SPF (greater than 4.2%) indicated short 10-year progression-free (P = 0.01 for ploidy and P = 0.0002 for SPF), overall (P = 0.004 and P less than 0.0001) as well as prostate cancer survival (P = 0.002 and P less than 0.0001). Ten-year overall survival rate was 45% in cases with SPF below 4.2% and 0% in those with higher values, whereas the corresponding prostate cancer-specific survival rates were 80% and 11%, respectively. None of the seven tumours with SPF above 12% showed an objective response to endocrine therapy, whereas 26/49 (52%) of those with lower SPF values responded (P = 0.01). DNA ploidy, tumour grade, T-stage or M-stage did not significantly correlate with endocrine responsiveness. SPF was also the best predictor of progression free survival in patients treated hormonally. In conclusion, detection of high SPF in prostate cancer may indicate lack of hormonal responsiveness and poor prognosis.
机译：我们通过DNA流式细胞术分析了78个石蜡包埋的原发性前列腺癌的倍性和S期分数（SPF）。 DNA非整倍性和高于中值（4.2％）SPF均与肿瘤高分级，前列腺大和远处转移有关。非整倍性和高SPF（大于4.2％）均表明10年无进展进展（倍性P = 0.01，SPF P = 0.0002），总体（P = 0.004和P小于0.0001）以及前列腺癌的存活率（P = 0.002并且P小于0.0001）。 SPF低于4.2％的患者的十年总生存率为45％，较高者为0％，而相应的前列腺癌特异性生存率分别为80％和11％。 SPF高于12％的7例肿瘤均未显示出对内分泌治疗的客观反应，而SPF值较低的26/49（52％）则有反应（P = 0.01）。 DNA倍性，肿瘤等级，T期或M期与内分泌反应性无显着相关性。 SPF还是激素治疗患者无进展生存的最佳预测指标。总之，在前列腺癌中检测到高SPF可能表明缺乏激素反应性和不良预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号